Cargando…

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat

AIMS: The efficacy of anti-proprotein convertase subtilisin/Kexin type 9 (PCSK9) monoclonal antibodies in patients with atherosclerotic cardiovascular disease (ASCVD) remains unclear. Therefore, this study aims to assess the effect of PCSK9 inhibitors (alirocumab and evolocumab) on ASCVD patients co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hong-Fei, Mao, Yu-Cheng, Xu, Xin-Yi, Zhao, Si-Yu, Han, Dan-Dan, Ge, Shi-Yao, Song, Kai, Geng, Chang, Tian, Qing-Bao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755489/ https://www.ncbi.nlm.nih.gov/pubmed/36531722 http://dx.doi.org/10.3389/fcvm.2022.1016802

Ejemplares similares

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
por: Ge, Xiaoyue, et al.
Publicado: (2021)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
por: Choi, Hye Duck, et al.
Publicado: (2023)

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
por: Allevi, Massimiliano, et al.
Publicado: (2023)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat
por: Geng, Chang, et al.
Publicado: (2023)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease
por: Gao, Fei, et al.
Publicado: (2022)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
por: Choi, Joshua, et al.
Publicado: (2017)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis
por: Liang, Di, et al.
Publicado: (2022)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
por: Shah, Syed Raza, et al.
Publicado: (2017)

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
por: Erviti, Juan, et al.
Publicado: (2022)

FRI097 A Case Of Evolocumab-induced Transaminitis Revealing A Gastrointestinal Melanoma
por: Nava Suarez, Corina, et al.
Publicado: (2023)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Benefits and risks of antihypertensive medication in adults with different systolic blood pressure: A meta-analysis from the perspective of the number needed to treat
por: Mao, Yucheng, et al.
Publicado: (2022)

Corrigendum: Benefits and risks of antihypertensive medication in adults with different systolic blood pressure: A meta-analysis from the perspective of the number needed to treat
por: Mao, Yucheng, et al.
Publicado: (2022)

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control
por: Ray, Kausik K., et al.
Publicado: (2016)

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients
por: Ou, Ziwei, et al.
Publicado: (2022)

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
por: Shah, Parth, et al.
Publicado: (2017)

Alirocumab effect on preventing periprocedural ischaemic events in coronary heart disease patients undergoing coronary stenting (APPEASE trial): study protocol of a multicentre, open-label, randomised controlled trial
por: Huang, Zhuoshan, et al.
Publicado: (2023)

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study
por: Banach, Maciej, et al.
Publicado: (2023)

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
por: Liang, Zhe, et al.
Publicado: (2021)

Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis
por: Zhou, Yimo, et al.
Publicado: (2021)

A Non-Linear Association of Triglyceride Glycemic Index With Cardiovascular and All-Cause Mortality Among Patients With Hypertension
por: Zhou, Dan, et al.
Publicado: (2022)

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
por: Jetty, Vybhav, et al.
Publicado: (2017)

Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials
por: Deng, Chang-Jiang, et al.
Publicado: (2023)

Sodium and potassium intake and risk of cardiovascular events and all-cause mortality: the Rotterdam Study
por: Geleijnse, Johanna M., et al.
Publicado: (2007)

microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation
por: de los Reyes-García, Ascensión M., et al.
Publicado: (2023)

The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population
por: Huang, Yu, et al.
Publicado: (2023)

Leukocyte Telomere Length Shortening Implies Plaque Instability and Major Adverse Cardiovascular Events in Patients With Angiographically Intermediate Lesions
por: Zhang, Alian, et al.
Publicado: (2022)

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
por: Vallejo‐Vaz, Antonio J., et al.
Publicado: (2018)

Novel Insight Into Long-Term Risk of Major Adverse Cardiovascular and Cerebrovascular Events Following Lower Extremity Arteriosclerosis Obliterans
por: Sun, Ji, et al.
Publicado: (2022)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

Prediabetes as a risk factor for major adverse cardiovascular events
por: Mando, Ramy, et al.
Publicado: (2021)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8em98ul8chubbdjq6l4h39nr9d